US Stock MarketDetailed Quotes
CARM Carisma Therapeutics
- 1.140
- +0.040+3.64%
Close Jul 23 16:00 ET
47.36MMarket Cap-583P/E (TTM)
1.150High1.070Low153.18KVolume1.070Open1.100Pre Close171.57KTurnover0.68%Turnover RatioLossP/E (Static)41.54MShares7.14452wk High4.35P/B25.66MFloat Cap0.99052wk Low--Dividend TTM22.51MShs Float51.357Historical High--Div YieldTTM7.27%Amplitude0.990Historical Low1.120Avg Price1Lot Size
About Carisma Therapeutics Company
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.
Company Profile
SymbolCARM
Company NameCarisma Therapeutics
Listing DateFeb 6, 2014
Founded2016
CEOMr. Steven Kelly
MarketNASDAQ
Employees107
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address3675 Market Street,Suite 200
CityPhiladelphia
ProvincePennsylvania
CountryUnited States of America
Zip Code19104
Websitehttp://carismatx.com
Company Executives
- Name
- Position
- Salary
- Steven Kelly
- Director, President and Chief Executive Officer
- 3.50M
- Richard S. Morris, C.P.A.
- Chief Financial Officer
- 1.66M
- Dr. Michael Klichinsky, PhD,Pharm.D.
- Chief Scientific Officer
- 1.60M
- Sanford S. Zweifach
- Chairman of the Board
- 271.55K
- Marella Thorell
- Director
- --
- Dr. David T. Scadden, M.D.
- Director
- --
- Michael P. Torok
- Independent Director
- 207.95K
- Dr. John A. Hohneker, M.D.
- Independent Director
- --
- Dr. Briggs W. Morrison, M.D.
- Independent Director
- 220.20K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg